Dyadic to Report 2022 Year End Financial Results on Wednesday, March 29, 2023

by B2i | Mar 15, 2023 | Press Releases

JUPITER, Fla., March 15, 2023 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...

Dyadic Provides Phase 1 Clinical Trial Update for its DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate

by B2i | Mar 7, 2023 | Press Releases

Dosing of all patients was completed at the end of February No Serious Adverse Events (SAE’s) have been reported Phase 1 clinical initial safety and antibody response update expected in Q2, 2023 JUPITER, Fla., March 07, 2023 — Dyadic International, Inc....

Dyadic to Present at Roth Investor Conference and Upcoming Industry Events

by B2i | Mar 1, 2023 | Press Releases

JUPITER, Fla., March 01, 2023 — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein...

Dyadic to Participate in Two Upcoming Investor Conferences

by B2i | Feb 2, 2023 | Press Releases

JUPITER, Fla., Feb. 02, 2023 — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein...

Dyadic Announces Initiation of Dosing of First-In-Human Phase 1 Trial to Demonstrate Clinical Safety and Antibody Response in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate

by B2i | Jan 24, 2023 | Press Releases

JUPITER, Fla., Jan. 24, 2023 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein...